FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
Lotimatou avorago bare									
hours per response:	0.5								
p soponoo.	0.0								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ODONNELL FRANCIS E JR						2. Issuer Name and Ticker or Trading Symbol BIODELIVERY SCIENCES INTERNATIONAL INC [BDSI]										all app	nship of Reporting F applicable) Director		10% Owner	
(Last)	` ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '					3. Date of Earliest Transaction (Month/Day/Year) 06/03/2019										Officer (give title below)			Other below)	(specify
4131 PARKLAKE AVENUE, SUITE 225					4. If Ar	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	H NC	2	7612												X		filed by One filed by Mor on		-	
(City)	(Sta	ate) (Z	Zip)																	
		Table	e I - N	Non-Deriv	ative S	ecu	rities	s Acc	uired,	Dis	posed o	f, o	r Ben	eficia	ally	Owne	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					/Year) i	Execution Date,			3. 4. Securities Acquired Disposed Of (D) (Instrand 5)					3, 4 Se Be Ov			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount		(A) or (D)	Price		Following Reported Transaction(s) (Instr. 3 and 4)		(III-Su . ·	- ,	(111341. 4)				
Common Stock ⁽¹⁾ 06/03/20					019			S		8,000		D	\$4.3	.32(2)		612,754)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any				ransaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			C. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			Ame Sec Und Der Sec	or Nu of	J	nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owr For Dire or I (I) (I 4)	nership m: ect (D) ndirect nstr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- 1. The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.
- 2. On June 3, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of \$4.32 per share. The highest sale price for the Common Stock was \$4.42 per share and the lowest sale price was \$4.26 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

Remarks:

/s/ Francis E. O'Donnell Jr. 06/05/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.